Ovarian cancer stands as the deadliest of all gynecologic malignancies, a reality driven primarily by late-stage diagnosis—most cases are identified only at Stage III or IV [1,2]. Clinical care for ovarian cancer follows a standard framework of disease staging, cytoreductive surgical intervention, and adjuvant platinum-based chemotherapy [3]. While 80% of patients respond favorably to this combined surgical and chemotherapeutic approach, the same percentage of initially treated patients experience cancer recurrence, necessitating return visits to gynecologic oncology specialists for additional treatment cycles [1]. This stark clinical challenge underscores an urgent need for novel therapeutic agents to advance ovarian cancer treatment and improve long-term survival outcomes for patients.
To address this unmet need, we have engineered two novel peptides—PNC-28 and PNC-27—each fusing the MDM2-binding domain of the p53 protein to a custom-designed membrane-active peptide we designate the membrane residency peptide (MRP). The amphipathic nature of the MRP moiety is a deliberate design feature: it enables each chimeric peptide to directly penetrate the lipid bilayer of the cellular plasma membrane, effectively bypassing endocytic pathways and the subsequent phagolysosomal degradation that limits the efficacy of many peptide-based agents [4–6].
A comprehensive series of in vitro investigations has validated that both PNC-28 and PNC-27 exert selective cytotoxic effects against a broad panel of cancer cell lines. Critically, these peptides show no cytotoxic activity toward non-transformed healthy cells, nor do they impact primary hematopoietic stem cells derived from human umbilical cord tissue [4–9]. Translating these in vitro findings to in vivo models, extended PNC-28 treatment successfully halted tumor growth and metastatic spread in immunodeficient Nu/Nu mice bearing xenotransplanted pancreatic cancer tumors [8].
A well-recognized critique of traditional drug development research is the reliance on long-established cancer cell lines, which undergo repeated selection during extended passaging. This process alters their cellular characteristics to the point where they no longer accurately reflect the original tumor cells from which they were isolated, limiting the translational relevance of study results to patient outcomes. This limitation underscores the critical importance of utilizing ex vivo primary cell cultures in preclinical research, as these models bridge the gap between in vitro experimentation and the in vivo tumor microenvironment, yielding results far more predictive of clinical behavior [10].
All prior demonstrations of PNC-28 and PNC-27’s selective cancer cell cytotoxicity have been conducted using long-established cancer cell lines [4–7], which raises a key research question: what is the efficacy of these peptides against primary human ovarian cancer cells? To answer this critical question, the present study evaluates the ex vivo sensitivity of primary ovarian cancer cells—isolated the same day as surgical tumor resection—to PNC-27 exposure.